Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sienna Biopharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2019 was -850.40%.
The historical rank and industry rank for Sienna Biopharmaceuticals's ROC (Joel Greenblatt) % or its related term are showing as below:
SNNAQ's ROC (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -297.52 * Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
Sienna Biopharmaceuticals's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Sienna Biopharmaceuticals ROC (Joel Greenblatt) % Related Terms
Sienna Biopharmaceuticals ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Sienna Biopharmaceuticals's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNNAQ vs GTHR, PPCB, HSTC: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Sienna Biopharmaceuticals's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sienna Biopharmaceuticals ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sienna Biopharmaceuticals's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -850.40% mean?
Sienna Biopharmaceuticals (SNNAQ) has a ROC (Joel Greenblatt) % of -850.40% as of Sep. 2019. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sienna Biopharmaceuticals and its competitors.
Is Sienna Biopharmaceuticals' ROC (Joel Greenblatt) % too high?
Sienna Biopharmaceuticals' current ROC (Joel Greenblatt) % is -850.40%.
How does Sienna Biopharmaceuticals' ROC (Joel Greenblatt) % compare to GTHR and PPCB?
Sienna Biopharmaceuticals' ROC (Joel Greenblatt) % of -850.40% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sienna Biopharmaceuticals and its competitors. Sienna Biopharmaceuticals's current ROC (Joel Greenblatt) % is -850.40%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sienna Biopharmaceuticals stock overvalued right now?
Sienna Biopharmaceuticals (SNNAQ) has a current ROC (Joel Greenblatt) % of -850.40%. The current ROC (Joel Greenblatt) % is -850.40%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sienna Biopharmaceuticals (SNNAQ), the current ROC (Joel Greenblatt) % is -850.40% as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNNAQ has been successfully added to your 
